Quick Answer
Rallybio Corp reported Diluted EPS of $1.59 per share (loss) for fiscal year 2025.
Rallybio Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.59 | +85.0% |
| 2024 | -$10.61 | -476.6% |
| 2023 | -$1.84 | +12.0% |
| 2022 | -$2.09 | -13.6% |
| 2021 | -$1.84 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.36 | +238.5% | +263.6% |
| June 30, 2025 | -$0.22 | +40.5% | -4.8% |
| March 31, 2025 | -$0.21 | +55.3% | +19.2% |
| September 30, 2024 | -$0.26 | +42.2% | +29.7% |
| June 30, 2024 | -$0.37 | +19.6% | +21.3% |
| March 31, 2024 | -$0.47 | -9.3% | -4.4% |
| September 30, 2023 | -$0.45 | +25.0% | +2.2% |
| June 30, 2023 | -$0.46 | +19.3% | -7.0% |
- Rallybio Corp showed an increase of +85.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Rallybio Corp’s diluted eps has grown by 13.6% (from $1.84 per share (loss) to $1.59 per share (loss)).
- The most recent figure is from Rallybio Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: